The company's mission is to develop improved treatments to currently available SSRI medications by using psychedelic molecules as the starting point. Psylo is building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials. The company's approach is to create medicines that are widely available to the public. Psylo's focus on next-generation psychedelics is driven by the potential for these molecules to treat mental health disorders such as depression and anxiety.